Overview

AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression

Status:
Completed
Trial end date:
2019-10-01
Target enrollment:
Participant gender:
Summary
The study will evaluate the safety and efficacy of AV-101.
Phase:
Phase 2
Details
Lead Sponsor:
VistaGen Therapeutics, Inc.
Treatments:
Antidepressive Agents